TYK Medicines, Inc (HKG:2410)
11.04
0.00 (0.00%)
Apr 17, 2026, 4:08 PM HKT
TYK Medicines Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 367.29 | 460.46 | 186.83 | 90.76 |
Trading Asset Securities | - | - | 6 | 152.73 |
Cash & Short-Term Investments | 367.29 | 460.46 | 192.83 | 243.49 |
Cash Growth | -20.24% | 138.79% | -20.80% | - |
Other Receivables | 30.68 | 3.47 | 1.79 | 1.86 |
Receivables | 30.68 | 3.47 | 1.79 | 1.86 |
Prepaid Expenses | 39.24 | 60.27 | 33.2 | 28.22 |
Other Current Assets | 3.83 | 44.77 | 5.88 | 1.17 |
Total Current Assets | 441.04 | 568.98 | 233.71 | 274.73 |
Property, Plant & Equipment | 231.96 | 209.84 | 249.85 | 190.2 |
Long-Term Investments | 5.81 | - | - | - |
Other Intangible Assets | 56.77 | 62.41 | 68.07 | 73.73 |
Other Long-Term Assets | 44.16 | 74.47 | 21.51 | 19.71 |
Total Assets | 779.74 | 915.69 | 573.14 | 558.36 |
Accounts Payable | 45.16 | 19.64 | 32.17 | 9.66 |
Accrued Expenses | 61.17 | 45.71 | 46.94 | 20.7 |
Short-Term Debt | 134.12 | 144.18 | - | - |
Current Portion of Leases | 14.85 | 26.19 | 22.23 | 23.49 |
Current Income Taxes Payable | 0.57 | 6.98 | 0.46 | 2.05 |
Other Current Liabilities | 51.9 | 46.39 | 1,199 | 906.33 |
Total Current Liabilities | 307.77 | 289.08 | 1,301 | 962.24 |
Long-Term Leases | 3.85 | 6.49 | 19.5 | 32.46 |
Long-Term Unearned Revenue | 44.17 | 44.36 | 48.28 | 24.83 |
Other Long-Term Liabilities | 137.34 | 103.21 | 84.41 | 39.58 |
Total Liabilities | 493.13 | 443.13 | 1,453 | 1,059 |
Common Stock | 380.07 | 370.84 | 307.36 | 287.99 |
Additional Paid-In Capital | - | 1,481 | 768.34 | 602.71 |
Retained Earnings | - | -1,396 | -1,009 | -626.67 |
Treasury Stock | -17.67 | - | - | - |
Comprehensive Income & Other | -75.73 | 13.18 | -951.08 | -769.97 |
Total Common Equity | 286.67 | 469.09 | -884.48 | -505.94 |
Minority Interest | -0.06 | 3.47 | 4.45 | 5.19 |
Shareholders' Equity | 286.61 | 472.56 | -880.03 | -500.75 |
Total Liabilities & Equity | 779.74 | 915.69 | 573.14 | 558.36 |
Total Debt | 152.81 | 176.85 | 41.73 | 55.95 |
Net Cash (Debt) | 214.47 | 283.62 | 151.1 | 187.54 |
Net Cash Growth | -24.38% | 87.70% | -19.43% | - |
Net Cash Per Share | 0.57 | 0.84 | 0.52 | 0.68 |
Filing Date Shares Outstanding | 380.07 | 370.84 | 307.36 | 277.82 |
Total Common Shares Outstanding | 380.07 | 370.84 | 307.36 | 277.82 |
Working Capital | 133.27 | 279.89 | -1,067 | -687.51 |
Book Value Per Share | 0.75 | 1.26 | -2.88 | -1.82 |
Tangible Book Value | 229.9 | 406.68 | -952.55 | -579.67 |
Tangible Book Value Per Share | 0.60 | 1.10 | -3.10 | -2.09 |
Buildings | 1.8 | - | - | - |
Machinery | 20.73 | 19.95 | 18.63 | 17.03 |
Construction In Progress | 178.67 | 143.38 | 139.17 | 65 |
Leasehold Improvements | 22.45 | 21.13 | 15.38 | 8.87 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.